Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending November 26, 2012. The report announces a voluntary open offer to increase GSK's ownership stake in its publicly-listed Indian subsidiary, GlaxoSmithKline Consumer Healthcare Ltd, from 43.2% to up to 75%.
Key Financial Metrics and Transaction Details
- Offer Price: INR 3,900 per share.
- Premium: Approximately 28% over the closing share price on November 23, 2012, and 22% over the 12-month high.
- Transaction Value: Approximately INR 52.2 billion (approx. £591 million).
- Shares to be Acquired: Up to 13,389,410 shares (representing 31.8% of total outstanding shares).
- Funding: To be funded through GSK's existing cash resources.
- Subsidiary Performance: The Indian Consumer Healthcare business generated over INR 28 billion turnover in the financial year ended December 31, 2011 (approx. £380 million), with a 5-year CAGR of 19%.
Material Changes and Accounting Impact
GSK will continue to consolidate 100% of the results and net assets of the Indian subsidiary. However, the share of profits attributable to non-controlling interests and the non-controlling interests balance on the balance sheet will decrease post-transaction. GSK will record no gain or loss on the acquisition; accounting entries will be recorded within non-controlling interests and shareholders' equity.
Outlook, Management Commentary, and Risks
- Strategic Rationale: The transaction aligns with GSK's strategy to invest in the world's fastest-growing markets and provides a liquidity opportunity for existing shareholders at an attractive premium.
- Earnings Impact: The transaction is expected to be earnings neutral in the first year and accretive thereafter.
- Capital Allocation: The deal will not impact expectations for the Group's long-term share buyback programme.
- Timeline: Subject to regulatory clearance, the offer period is expected to begin in January 2013.
- Risks: Forward-looking statements are subject to risks and uncertainties described in the "Risk factors" section of the GSK Annual Report 2011.
Investor Verification Checklist
- Verify the final acceptance rate of the voluntary open offer and the resulting ownership percentage.
- Confirm regulatory clearance status from the Securities and Exchange Board of India (SEBI).
- Monitor the actual cash outflow against the projected £591 million transaction value.
- Review future quarterly reports to confirm the "earnings neutral" and "accretive" projections.
- Check for any changes in the non-controlling interest line items in subsequent balance sheets.